ABIVAX Société Anonyme (ABVX.PA) Stock Price
€59.7 0.5%
to add to portfolio
AI Score
-
Alternative
8 -
Fundamental
7 -
Technical
8
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on ABIVAX Société Anonyme, AI stock picks, stock alerts and much more.
ABVX.PA AI Stock Analysis
AI stock analysis for ABVX.PA is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like ABIVAX Société Anonyme (ABVX.PA) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
ABIVAX Société Anonyme (ABVX.PA) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of ABIVAX Société Anonyme (ABVX.PA), currently trading at €59.7, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About ABVX.PA
-
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France.
-
Symbol
ABVX.PA
-
Market
EURONEXT
-
Industry
Biotechnology
-
Market Cap
4.5B
Similar Stocks
 |
Valneva SE VLA.PA |
€5.07 6.1% |
5 |
 |
Financière de Tubize SA TUB.BR |
€160 1.7% |
8 |
 |
OSE Immunotherapeutics SA OSE.PA |
€6.91 4.1% |
7 |
 |
UCB SA UCB.BR |
€195.5 1.5% |
6 |
 |
Innate Pharma S.A. IPH.PA |
€1.99 1.4% |
6 |
News
ABVX.PA Alternative Data
Web Traffic
ABIVAX Société Anonyme receives an estimated 25384 monthly visitors to abivax.com.
-
Web Traffic
25384
-
Change from Previous Month
370.8%
-
3 Month Change
497.4%
-
YoY Change
497.4%
Twitter Followers
ABIVAX Société Anonyme has 1,322 Twitter Followers on its main Twitter (also known as X) account, which is up by 4% over the last month.
-
Twitter Followers
1322
-
Daily Change
0.2%
-
1 Month Change
4%
-
3 Month Change
4.5%
-
YoY Change
4.5%
Job Postings
ABIVAX Société Anonyme currenly has an estimated 0 open job postings.
-
Job Postings
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
Reddit Mentions
ABIVAX Société Anonyme has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
LinkedIn Followers
13,646 are following ABIVAX Société Anonyme on LinkedIn, up by 10% over the last month.
-
LinkedIn Followers
13646
-
Daily Change
10%
-
1 Month Change
10%
-
3 Month Change
13.1%
-
YoY Change
13.1%
LinkedIn Employees
According to LinkedIn, ABIVAX Société Anonyme has 88 employees.
-
LinkedIn Employees
88
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
2.2%
-
YoY Change
2.2%
Business Outlook
According to employee reviews, the business outlook among employees at ABIVAX Société Anonyme is 66 out of 100 (bullish).
-
Business Outlook
66
-
Change from Previous Month
0%
-
3 Month Change
0%
-
YoY Change
0%
News Mentions
ABIVAX Société Anonyme was mentioned 0 times in the news yesterday.
-
News Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
ABVX.PA Financials
ABVX.PA Key Metrics
-
Total Revenue
€6.8M
-
Net Income
-€81.6M
-
Earnings per Share
-€1.3
-
Free cash flow
-€85.4M
-
EBITDA
-€79.8M
-
EBITDA Ratio
-11.7632
-
Total Assets
€205.2M
ABVX.PA 2-year Revenue & Income
ABVX.PA 2-year Free Cash Flow
ABVX.PA Technicals
ABVX.PA SMA
ABVX.PA RSI
FAQ
What's the current price of ABIVAX Société Anonyme (ABVX.PA) Stock?
The price of an ABIVAX Société Anonyme (ABVX.PA) share is €59.7.
What's the market cap of ABIVAX Société Anonyme?
The current market cap of ABIVAX Société Anonyme is 4.5B.
Should I buy or sell ABVX.PA?
Multiple alternative data signals suggest that ABIVAX Société Anonyme stock could offer a buying opportunity at its current level, with a reasonable expectation for positive performance in the mid term.
Is ABIVAX Société Anonyme a good investment?
Based on an in-depth analysis that encompasses fundamentals, technical analysis, and alternative data insights, it appears to be a favorable time to consider investing in ABIVAX Société Anonyme stock. The bullish indicators suggest that ABIVAX Société Anonyme's growth prospects and market position may lead to a positive performance in the foreseeable future.
Is now a good time to buy ABIVAX Société Anonyme (ABVX.PA) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, it could be a favorable time to consider buying ABIVAX Société Anonyme stock, given the bullish outlook.
What are some stocks similar to ABIVAX Société Anonyme (ABVX.PA) that investors often compare it to?
ABIVAX Société Anonyme (ABVX.PA) is often compared to similar stocks such as Valneva SE, Financière de Tubize SA, OSE Immunotherapeutics SA, UCB SA and Innate Pharma S.A..
What is the forecast for ABIVAX Société Anonyme's stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast ABIVAX Société Anonyme's stock price to be around €66.25 in 2026. Starting from the current price of €59.7, this represents a 11% change in price, indicating a bullish outlook for the stock.
How to buy ABIVAX Société Anonyme (ABVX.PA) Stock?
ABIVAX Société Anonyme stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy ABIVAX Société Anonyme shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.